Patents Assigned to Institut Pasteur
  • Patent number: 11618781
    Abstract: The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: April 4, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel, Francois Traincard, Laurence Mulard
  • Patent number: 11566280
    Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 31, 2023
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti
  • Patent number: 11559575
    Abstract: The invention relates to multi-epitopic peptide compounds obtained from PSA, HwB and LmLRAB proteins of Leishmania as well as to pharmaceutical compositions and vaccines for use against one or more leishmaniases.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: January 24, 2023
    Assignees: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, INSTITUT PASTEUR DE TUNIS
    Inventors: Rachel Bras Gonçalves, Jean-Loup Lemesre, Amel Garnaoui, Elodie Petitdidier-Lesin
  • Patent number: 11530452
    Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 20, 2022
    Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
  • Patent number: 11504049
    Abstract: A kit of two compositions comprising the same odorants in mixtures of different proportions is used for the measurement of olfactory discrimination capacity in subjects affected by a psychiatric disorder or disease involving mood disturbance, more particularly mood depression.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 22, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francoise Lazarini, Pierre-Marie Lledo, Eleni Siopi, Raphael Servignat D'Aout
  • Patent number: 11498942
    Abstract: The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 15, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: John P. Bannantine, Gilles Etienne, Sylvie Bay, Franck Biet
  • Patent number: 11472844
    Abstract: The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the capability to interact at least with: neutrophils and/or neutrophil granules, and/or lactoferrin, and/or globet-cells and/or Muc2 proteins, and/or mucus and/or airway sputum. The peptidomimetic may have the capacity to adopt a multimeric, especially a trimeric, organization, and can be labelled, or associated with a reporter or a carrier entity, or associated with an active molecule. The invention also relates to a Solid-Phase Synthesis method for synthesizing a peptidomimetic of the invention, compositions comprising the same and use of the peptidomimetics as a medicamentor an inflammation marker or a neutrophilic inflammation marker.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: October 18, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Benoit Sebastien Marteyn, Yves-Marie Coic, Francoise Baleux
  • Publication number: 20220317131
    Abstract: The invention relates to the quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or Cerebrospinal Fluid (CSF). The invention also relates to an in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved, to an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. The invention also relates to a kit to quantitate said specific antibodies for at least one redox form of HMGB1, in particular human HMGB1.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 6, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise GOUGEON, Nicole PRADA, Hela SAIDI
  • Patent number: 11460473
    Abstract: Quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved. An in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. A kit to quantitate said specific antibodies for at least one redox form of HMGB1.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 4, 2022
    Assignee: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Nicole Prada, Hela Saidi
  • Publication number: 20220296546
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: INSTITUT PASTEUR DE MONTEVIDEO, UNIVERSIDAD DE LA REPÚBLICA
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, Maria Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Patent number: 11447486
    Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, in
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 20, 2022
    Assignees: INSTITUT PASTEUR KOREA, QURIENT CO., LTD.
    Inventors: Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Dongsik Park, Young-In Yang, Doohyung Lee, Saeyeon Lee, Jiye Ahn, Jeongjun Kim, Kiyean Nam, Sunhee Kang, Minjung Seo, Mooyoung Seo, Jeongjea Seo, Sung-Jun Han, Jung Hwan Kim, Sangchul Lee, Gahee Choi, Yunmi Lee
  • Patent number: 11446372
    Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 20, 2022
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
  • Patent number: 11434585
    Abstract: The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 6, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frédéric Pecorari, Pedro Alzari
  • Patent number: 11400066
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: August 2, 2022
    Assignees: INSTITUT PASTEUR DE MONTEVIDEO, UNIVERSIDAD DE LA REPÚBLICA
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez
  • Publication number: 20220233678
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Application
    Filed: March 14, 2022
    Publication date: July 28, 2022
    Applicants: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude ROTH, Etienne SIMON-LORIERE, Anavaj SAKUNTABHAI, Felix DELGADO
  • Publication number: 20220233503
    Abstract: Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 28, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Tarek SHARSHAR, Fabrice CHRETIEN, Aurelien MAZERAUD, Fernando Augusto BOZZA
  • Publication number: 20220226307
    Abstract: The invention provides methods of reducing development of mild cognitive impairment and/or learning disorders and/or memory disorders in a subject suspected to have or suffering from Alzheimer's disease (AD). In some embodiments, the methods comprise administering a therapeutically effective amount of a beta-2 nicotinic acetylcholine receptor (nAChR) antagonist and/or beta-2 nAChR negative allosteric modulator (NAM) to the subject over a therapeutic dosing period to thereby reduce the rate of development of mild cognitive impairment and/or learning disorders and/or memory disorders in the subject over the therapeutic dosing period.
    Type: Application
    Filed: December 20, 2021
    Publication date: July 21, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Uwe MASKOS, Sylvia LOMBARDO, Julie CATTEAU, Morgane BESSON, Fani KOUKOULI
  • Patent number: 11384345
    Abstract: The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 12, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Marc Delarue, Volahasina (Irina) Randrianjatovo Gbalou
  • Patent number: 11384346
    Abstract: The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for partial or full deletion of at least one DNA tandem repeat in a double-stranded DNA, more particularly for partial or full deletion of at least one DNA tandem repeat, which is contained in a double-stranded DNA and, which forms a complex secondary structure, such as a hairpin, a triple helix or a tetraplex secondary structure. The means of the application are notably useful in the treatment and/or prevention and/or palliation of a disease or disorder involving at least one DNA tandem repeat, such as DM1, SCA8, SCA12, HDL2, SBMA, HD, DRPLA, SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, PSACH, DM2, SCA10, SPD1, OPMD, CCD, HPE5, HFG syndrome, BPES, EIEE1, FRAXA, FXTAS and FRAXE.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 12, 2022
    Assignee: INSTITUT PASTEUR
    Inventors: Guy-Franck Richard, Valentine Mosbach, David Viterbo
  • Patent number: 11369670
    Abstract: The invention relates to Plasmodium antigenic polypeptides identified through the use of a specifically devised functional immunization screening assay. In particular, the invention relates to antigenic polypeptides of malaria parasites wherein said antigenic polypeptides that exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites. The invention relates to a combination of compounds, comprising at least 2 distinct active ingredients wherein each active ingredient consists of an antigenic polypeptide of a Plasmodium parasite, a polynucleotide encoding the antigenic polypeptide, or a vector, in particular a viral vector, especially a lentiviral vector, expressing such antigenic polypeptide of a Plasmodium parasite, wherein one antigenic polypeptide is the circumsporozoite protein (CSP) or a polypeptidic derivative thereof and another antigenic polypeptide is either protein Ag40 (11-09) or protein Ag45 (11-10).
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 28, 2022
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Rogerio Amino, Pierre Charneau, Anne-Sophie Beignon, Catherine Blanc